WO1998017325A3 - Covalent polar lipid conjugates for targeting - Google Patents

Covalent polar lipid conjugates for targeting Download PDF

Info

Publication number
WO1998017325A3
WO1998017325A3 PCT/US1997/019486 US9719486W WO9817325A3 WO 1998017325 A3 WO1998017325 A3 WO 1998017325A3 US 9719486 W US9719486 W US 9719486W WO 9817325 A3 WO9817325 A3 WO 9817325A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeting
drugs
agents
neurotropic
psychotropic
Prior art date
Application number
PCT/US1997/019486
Other languages
French (fr)
Other versions
WO1998017325A2 (en
Inventor
Milton B Yatvin
Michael H B Stowell
Michael J Meredith
Original Assignee
Univ Oregon Health Sciences
Milton B Yatvin
Michael H B Stowell
Michael J Meredith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health Sciences, Milton B Yatvin, Michael H B Stowell, Michael J Meredith filed Critical Univ Oregon Health Sciences
Priority to CA002269947A priority Critical patent/CA2269947C/en
Priority to JP51970998A priority patent/JP2002514188A/en
Priority to AU50909/98A priority patent/AU738524C/en
Priority to EP97913811A priority patent/EP0944399A2/en
Publication of WO1998017325A2 publication Critical patent/WO1998017325A2/en
Publication of WO1998017325A3 publication Critical patent/WO1998017325A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

This invention herein describes a method of facilitating the entry of drugs into cells and tissues at physiologically protected sites at pharmicokinetically useful levels and also a method of targeting drugs to specific organelles within the cell. This polar lipid/drug conjugate targeting invention embodies an advance over other drug targeting methods known in the prior art, because the invention provides drug concentrations in such physiologically protected sites that can reach therapeutically-effective levels after administration of systemic levels much lower than are currently administered to achieve a therapeutic dose. This technology is appropriate for use with psychotropic, neurotropic and neurological drugs, agents and compounds, for rapid and efficient introduction of such agents across the blood-brain barrier. Further, the invention provides means for retention and prolonged enzymatic release of psychotropic, neurotropic and neurological drugs, agents and compounds comprising the conjugates of the invention, in the brain and central nervous system.
PCT/US1997/019486 1996-10-25 1997-10-27 Covalent polar lipid conjugates for targeting WO1998017325A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002269947A CA2269947C (en) 1996-10-25 1997-10-27 Covalent polar lipid conjugates for targeting
JP51970998A JP2002514188A (en) 1996-10-25 1997-10-27 Targeted covalent polar lipid complexes
AU50909/98A AU738524C (en) 1996-10-25 1997-10-27 Covalent polar lipid conjugates for targeting
EP97913811A EP0944399A2 (en) 1996-10-25 1997-10-27 Covalent polar lipid conjugates for targeting

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/735,977 1996-10-25
US08/735,977 US5827819A (en) 1990-11-01 1996-10-25 Covalent polar lipid conjugates with neurologically active compounds for targeting

Publications (2)

Publication Number Publication Date
WO1998017325A2 WO1998017325A2 (en) 1998-04-30
WO1998017325A3 true WO1998017325A3 (en) 1998-06-04

Family

ID=24957963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/019486 WO1998017325A2 (en) 1996-10-25 1997-10-27 Covalent polar lipid conjugates for targeting

Country Status (5)

Country Link
US (3) US5827819A (en)
EP (1) EP0944399A2 (en)
JP (1) JP2002514188A (en)
CA (1) CA2269947C (en)
WO (1) WO1998017325A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238616B2 (en) 2001-06-11 2016-01-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
AU1628799A (en) * 1998-12-04 2000-06-26 Oregon Health Sciences University Covalent polar lipid conjugates with antimicrobial and antineoplastic drugs for targeting to biological protected sites
WO2000033884A1 (en) * 1998-12-04 2000-06-15 Oregon Health Sciences University Conjugates of lipids and antimicrobial or antineoplastic drugs
JP2002535289A (en) * 1999-01-22 2002-10-22 ドウアリング，マシユー・ジヨン Vaccine-mediated treatment of neurological disorders
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
DE19926154A1 (en) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Process for the preparation of an injectable pharmaceutical preparation
DE60032255T2 (en) * 1999-10-04 2007-06-28 Nektar Therapeutics Al, Corp., Huntsville POLYMER-STABILIZED NEUROPEPTIDES
EP1267935A2 (en) 2000-01-12 2003-01-02 Light Sciences Corporation Novel treatment for eye disease
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (en) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 Methods and compositions for treating flaviviruses and pestiviruses
AP1466A (en) * 2000-07-21 2005-09-22 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
WO2002014264A2 (en) 2000-08-11 2002-02-21 The Brigham And Women's Hospital, Inc. (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
US20040253891A1 (en) * 2000-09-12 2004-12-16 Schierenbeck Alan W. Composite structure for protective garment
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
ES2387562T3 (en) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugates fatty alcohol-medication
WO2002076402A2 (en) 2001-03-23 2002-10-03 Protarga, Inc. Fatty amine drug conjugates
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN101434572B (en) * 2001-06-11 2013-03-13 什诺波特有限公司 Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
ATE540678T1 (en) * 2001-06-11 2012-01-15 Xenoport Inc GABA ANALOG PRODRUGS, COMPOSITIONS AND USES THEREOF
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US7217696B2 (en) 2002-02-28 2007-05-15 A & D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
US20050255038A1 (en) * 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7456155B2 (en) * 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
BRPI0313148B8 (en) * 2002-07-29 2021-05-25 Glaxo Group Ltd solid matrix formulations of lamotrigine containing outer coating and perforation in such coating
US20040152769A1 (en) * 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
KR20050109918A (en) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 Process for the production of 2'-branched nucleosides
EP1631259A4 (en) * 2002-12-18 2006-08-02 Hough Ear Inst Otologic nanotechnology
NZ543138A (en) * 2003-03-31 2009-02-28 Xenoport Inc Treating or preventing hot flashes using prodrugs of GABA analogs
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
WO2004112767A1 (en) * 2003-06-19 2004-12-29 Advanced Bionutriton Corporation Improved absorption of fat-soluble nutrients
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2005007240A1 (en) * 2003-07-21 2005-01-27 Vasogen Ireland Limited Combination treatment of neurological disorders comprising phospholipids
US20050143371A1 (en) * 2003-07-23 2005-06-30 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7700652B2 (en) * 2003-09-11 2010-04-20 Xenoport, Inc. Treating urinary incontinence using prodrugs of GABA analogs
CA2538802C (en) * 2003-09-17 2015-01-27 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
WO2005046676A1 (en) * 2003-11-12 2005-05-26 University Of South Carolina Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic amp-specific phosphodiesterase inhibitors
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
US7501397B2 (en) * 2004-06-04 2009-03-10 The Brigham And Women's Hospital, Inc. Helical peptidomimetics with enhanced activity
WO2005118612A1 (en) * 2004-06-04 2005-12-15 Sonus Pharmaceuticals, Inc. Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
US7342131B2 (en) * 2004-06-04 2008-03-11 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
BRPI0512360A (en) * 2004-06-23 2008-03-11 Idenix Cayman Ltd 5-aza-7-deazapurine derivatives for the treatment of flaviviridae
US8795725B2 (en) * 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
WO2006052790A2 (en) * 2004-11-05 2006-05-18 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
MX2007005507A (en) * 2004-11-12 2008-03-13 Neurochem Int Ltd Methods and fluorinated compositions for treating amyloid-related diseases.
JP2008520647A (en) * 2004-11-16 2008-06-19 ニューロケム （インターナショナル） リミテッド Compounds for the treatment of CNS and amyloid-related diseases
AU2005326962A1 (en) 2004-12-22 2006-08-17 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
JP4516863B2 (en) * 2005-03-11 2010-08-04 株式会社ケンウッド Speech synthesis apparatus, speech synthesis method and program
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007009012A2 (en) * 2005-07-13 2007-01-18 Al Czap Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
PT1959948E (en) * 2005-12-05 2012-09-12 Xenoport Inc Levodopa prodrug mesylate, compositions thereof, and uses thereof
EP1976382B1 (en) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
WO2007114948A2 (en) * 2006-04-04 2007-10-11 The Brigham And Women's Hospital, Inc. Methods and compositions for inhibiting cell death
US20100316626A1 (en) * 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
EA016568B1 (en) 2006-10-12 2012-05-30 Беллус Хелс (Интернэшнл) Лимитед Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US20080161393A1 (en) * 2006-12-08 2008-07-03 Barrett Ronald W Use of prodrugs of GABA analogs for treating disease
TW200843731A (en) * 2006-12-21 2008-11-16 Xenoport Inc Catechol protected levodopa diester prodrugs, compositions, and methods of use
US7709527B2 (en) * 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2010035261A2 (en) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
JP2013520521A (en) 2009-11-09 2013-06-06 ゼノポート，インコーポレーテッド Pharmaceutical composition and oral dosage form of levodopa prodrug and method of use
US9415113B2 (en) * 2009-11-18 2016-08-16 University Of Washington Targeting monomers and polymers having targeting blocks
NZ736131A (en) * 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA3066077A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
US11453701B2 (en) 2017-08-18 2022-09-27 Adrx, Inc. Tau aggregation peptide inhibitors
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20230023092A1 (en) 2019-04-17 2023-01-26 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780455A (en) * 1985-04-12 1988-10-25 The Trustees Of Columbia University In The City Of New York Lipophilic complexes of pharmacologically active organic compounds
DE3726945A1 (en) * 1987-08-13 1989-02-23 Dietl Hans L-Carnitine derivatives of valproic acid and pharmaceuticals containing these
US4810697A (en) * 1981-10-16 1989-03-07 Peter Speiser Pharmaceutical formula
WO1994001138A1 (en) * 1992-07-09 1994-01-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Covalent polar lipid-peptide conjugates for biological targeting
WO1994022483A2 (en) * 1993-03-31 1994-10-13 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
WO1996004001A1 (en) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5525727A (en) * 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
DE3228557A1 (en) * 1982-07-30 1984-02-09 Ulrich 8000 München Trampnau WARNING DEVICE FOR HELICOPTER
DE3343530A1 (en) * 1983-12-01 1985-06-13 Max Planck Gesellschaft MEDICINE WITH IMPROVED PENETRATION OF THE TISSUE MEMBRANE
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
DE3683688D1 (en) * 1985-04-19 1992-03-12 Wistar Inst VACCINE FOR THE GENERATION OF AN IMMUNOGENIC T-CELL REPLY PROTECTING A VIRUS.
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
US5039794A (en) * 1986-09-19 1991-08-13 Otsuka Pharmaceutical Co., Ltd. Tumor egress factor and processes for producing the same
US4793986A (en) * 1987-02-25 1988-12-27 Johnson Matthey, Inc. Macromolecular platinum antitumor compounds
AU630591B2 (en) * 1987-07-06 1992-11-05 Peptide Technology Limited Growth hormone related peptide
US4902641A (en) * 1987-07-31 1990-02-20 Motorola, Inc. Process for making an inverted silicon-on-insulator semiconductor device having a pedestal structure
SE459584B (en) * 1987-10-02 1989-07-17 Studsvik Ab PROCEDURES FOR PROCESSING OF RAAGAS MANUFACTURED FROM COAL CONTENTS
US5053394A (en) * 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
EP0388434A4 (en) * 1987-11-18 1990-12-19 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Differential delivery of therapeutic agents across the blood brain barrier
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5284876A (en) * 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
GB2217319A (en) * 1988-04-19 1989-10-25 Synpharm Ltd Racemic and optically active fatty amino acids, their homo- abd hetero-oligomers and conjugates, the process of their production, their pharmaceutical composi
AU3757789A (en) * 1988-05-18 1989-12-12 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates
AU587363B1 (en) * 1988-07-27 1989-08-10 Richard Henry Tollervey Improvements to helicopter rotor blades
DE8812762U1 (en) * 1988-10-11 1989-06-29 Emitec Emissionstechnologie
WO1990010448A2 (en) * 1989-03-07 1990-09-20 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
EP0484403A4 (en) * 1989-07-27 1993-03-17 Univax Biologics Incorporated Lipid a analog/immunogenic carrier conjugates and the use thereof as vaccines
DE3927209A1 (en) * 1989-08-17 1991-02-21 Iro Ab DEVICE FOR SECURING THE WRAPPING OF A ROLL WRAPPING IN A TEXTILE COIL WINDING DEVICE
DK437289D0 (en) * 1989-09-04 1989-09-04 Hans Bundgaard PRODUCT DERIVATIVES OF THYROTROPIN-RELEASING HORMONE (TRH)
WO1991004014A1 (en) * 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
JPH05500504A (en) * 1989-09-27 1993-02-04 アテナ・ニュウロサイエンスィズ・インコーポレイテッド Composition and method of use for inhibiting cell adhesion
JPH03236315A (en) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd Antipsychotic agent
AU654811B2 (en) * 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6517859B1 (en) * 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
AU660417B2 (en) * 1990-06-15 1995-06-29 University Of North Carolina At Chapel Hill, The Ether lipid-nucleoside covalent conjugates
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5270312A (en) * 1990-11-05 1993-12-14 Warner-Lambert Company Substituted piperazines as central nervous system agents
US5254342A (en) * 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
KR20030097604A (en) * 1992-07-13 2003-12-31 유카리언, 인코포레이티드 A composition for delivering a lipidized immunoglobulin to an intracellular compartment of a cell, a lipidized protein, and a lipidized antibody
DE69328430T2 (en) * 1992-07-27 2001-01-25 Us Health TARGETED LIPOSOME TO THE BLOOD BRAIN CABINET
JP2804177B2 (en) * 1992-07-30 1998-09-24 株式会社ディ・ディ・エス研究所 Brain-retaining compound and its use
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
EP0753071A1 (en) * 1993-04-28 1997-01-15 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
US5434137A (en) * 1993-05-10 1995-07-18 Black; Keith L. Method for selective opening of abnormal brain tissue capillaries
WO1995007092A1 (en) * 1993-09-10 1995-03-16 The University Of Medicine And Dentistry Of New Jersey Blood-brain barrier transporters of neurological agents
AU1947395A (en) * 1994-02-28 1995-09-11 Medinova Medical Consulting Gmbh Drug targeting system, method for preparing same and its use
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810697A (en) * 1981-10-16 1989-03-07 Peter Speiser Pharmaceutical formula
US4780455A (en) * 1985-04-12 1988-10-25 The Trustees Of Columbia University In The City Of New York Lipophilic complexes of pharmacologically active organic compounds
DE3726945A1 (en) * 1987-08-13 1989-02-23 Dietl Hans L-Carnitine derivatives of valproic acid and pharmaceuticals containing these
WO1994001138A1 (en) * 1992-07-09 1994-01-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Covalent polar lipid-peptide conjugates for biological targeting
WO1994022483A2 (en) * 1993-03-31 1994-10-13 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
WO1996004001A1 (en) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 47, no. 5, 1995, Philadelphia, PA, US; abstract no. 077435, YATVIN M. B. ET AL: "Targeting lipophilic prodrugs to brain, lung and spleen" XP002061069 *
KEYSTONE SYMPOSIUM ON DRUG DELIVERY: BARRIERS TO DRUG TRANSPORT AND THE DESIGN OF NOVEL THERAPEUTIC AGENTS, 7 January 1995 (1995-01-07), SOUTH CAROLINA, USA *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238616B2 (en) 2001-06-11 2016-01-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof

Also Published As

Publication number Publication date
EP0944399A2 (en) 1999-09-29
WO1998017325A2 (en) 1998-04-30
CA2269947C (en) 2002-08-13
AU738524B2 (en) 2001-09-20
JP2002514188A (en) 2002-05-14
US6024977A (en) 2000-02-15
CA2269947A1 (en) 1998-04-30
US5827819A (en) 1998-10-27
US6436437B1 (en) 2002-08-20
AU5090998A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
WO1998017325A3 (en) Covalent polar lipid conjugates for targeting
WO2003039677A3 (en) Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
CN1777411B (en) Transmucosal drug delivery system
WO2001019406A3 (en) Amphiphilic prodrugs
US6627211B1 (en) Transnasal anticonvulsive compositions and modulated process
CA2184242A1 (en) Drug Targeting System, Method for Preparing Same and Its Use
CA2198245A1 (en) Methods and means for drug administration
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
ES2176432T3 (en) TREATMENT OF CEREBRAL ISCHEMIA AND BRAIN INJURY THROUGH A NEUROPROTECTOR AGENT.
TW200800223A (en) Transdermal delivery of meptazinol
WO2004043334A3 (en) Administration of anti-inflammatory drugs into the central nervous system
HK1025915A1 (en) Method of treating dry eye disease with purinergicreceptor agonist.
IL130823A0 (en) Peptide-lipid conjugates liposomes and liposomal drug delivery
WO2003103596A8 (en) Stabilized nanoparticle formulations of camptotheca derivatives
JP2002531489A5 (en)
CA2301799A1 (en) Novel conjugates of opioids and endogenous carriers
BG106221A (en) Morphine-containing intranasal pharmaceutical preparations and methods for their administration
HK1048266A1 (en) Pharmaceutically stable oxaliplatinum preparation for parenteral administration.
WO2001028542A3 (en) Combination therapy including camptothecin
AU2313297A (en) Transdermally administered dextromethorphan as antitussive agent
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
WO2000035418A3 (en) Chewable drug delivery system
Goldstein et al. Effect of substance P on medial forebrain bundle self-stimulation in rats following intracerebral administration
CA2261887A1 (en) Covalent polar lipid conjugates with biologically-active compounds for use in salves
US20050288292A1 (en) Pharmaceutical formulation and its use in the treatment of inner ear diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2269947

Country of ref document: CA

Ref country code: CA

Ref document number: 2269947

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 50909/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1997913811

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997913811

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 50909/98

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1997913811

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997913811

Country of ref document: EP